27 results about "Obesity resistant" patented technology

The present invention relates to a Korean microbiome-derived Clostridium butyricum strain having anti-obesity efficacy and a use thereof. The strain has an excellent effect of reducing the body weight and adipose tissue weight of experimental animals compared to a control group (strain-untreated) under high-fat diet conditions, has an excellent effect of reducing the content of total cholesterol, triglycerides, low-density lipoprotein (LDL), leptin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in serum, and has an excellent effect of reducing blood glucose and increasing the content of glucagon-like peptide-1 (GLP-1) in an oral glucose load test, and is thus expected to be effectively used as an ingredient in a composition for preventing, alleviating, or treating obesity and metabolic diseases caused by obesity.

The invention discloses application of knockout or inhibition of intestinal epithelium Ufbp1 gene expression in preparation of medicines for preventing and / or treating obesity, and belongs to the technical field of biological medicines. In order to solve the problems of limited effect, many side effects and the like of the existing obesity treatment means, the invention provides Ufbp1 specifically expressed by intestinal epithelial cells as a new anti-obesity intervention target for the first time. By knocking out or inhibiting intestinal epithelium Ufbp1, weight gain, adipose tissue accumulation, hyperlipidemia, liver fatty degeneration and insulin resistance induced by high fat diet can be effectively resisted. The action mechanism is related to influence on secretion of intestinal apolipoprotein ApoB48 / ApoA1 and further regulation and control of whole body lipid metabolism. The invention provides a clear target and theoretical basis for developing novel anti-obesity therapies such as small-molecule inhibitors and nucleic acid drugs of targeted intestinal epithelium Ufbp1, and has important clinical transformation prospects.

The invention provides fermented black beans with an anti-obesity effect as well as a preparation method and application of the fermented black beans, and relates to the field of fermented products. The preparation method comprises the following steps: soaking cleaned black beans with a polygonatum sibiricum enzymatic hydrolysate; sterilizing the soaked black beans, inoculating rhizopus, lactic acid bacillus and lactobacillus plantarum, and carrying out mixed fermentation; and drying the fermented black beans to obtain the fermented black beans with the anti-obesity effect. Through verification, the prepared fermented black beans can effectively relieve damage of a high-fat environment to the reproductive capacity of the nematodes, improve the automatic swimming capacity of the nematodes, improve the activity of antioxidant enzymes in the nematodes and remarkably reduce the content of triglyceride and free fatty acid in the high-fat nematodes, and the fermented black beans are proved to have a remarkable anti-obesity effect; meanwhile, the fermented black beans also have excellent sensory quality. The method overcomes the defects of poor sensory quality and poor function guidance of the fermented black beans in the prior art.

The present invention relates to Akkermansia muciniphila SNUG-61027 strain (accession number KCTC 13530BP) and use thereof, specifically, a composition for suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases, comprising the strain, or a culture solution thereof, etc. or a B2UM07 protein isolated therefrom as an active ingredient, and use thereof for suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases, and a method of suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases using the same are provided. Through this, among the anti-obesity effects, not only weight reduction and glucose homeostasis regulation, but also the effect on brown fat and the effect of secreting appetite regulating hormones are exhibited.

This invention discloses the application of a high-N-acetylglycine-producing *Lactobacillus reuteri* strain in alleviating obesity-related metabolic diseases, belonging to the field of microbial technology. The *Lactobacillus reuteri* NO1 strain of this invention (…) Limosilactobacillus reuteri (NO1) possesses the ability to produce N-acetylglycine in vitro. This strain can inhibit weight gain in obese mice without affecting food intake; improve glucose tolerance in obese mice while reducing blood glucose, serum insulin, and insulin resistance index; regulate liver triglycerides in obese mice, and alleviate liver tissue damage. The *Lactobacillus reuteri* strain described in this invention has very broad application prospects for preparing anti-obesity pharmaceutical compositions and fermented foods.

The present invention relates to a peptide having muscle formation-promoting activity, anti-obesity activity, fatty liver-inhibiting activity, or anti-diabetic activity, and to a use thereof. Specifically, the peptide of the present invention exhibits activities of inhibiting muscle loss, increasing muscle mass, promoting lipid degradation in hepatocytes or adipocytes, suppressing insulin resistance signaling, or enhancing insulin sensitivity signaling. The peptide of the present invention can be effectively used as an active ingredient in a pharmaceutical composition or a food composition for treating, preventing, or alleviating muscle diseases, obesity, fatty liver, or diabetes.

This invention relates to peptide complexes with anti-diabetic activity and their uses. The peptide complexes of this invention promote cellular glucose uptake, inhibit insulin resistance signaling, promote insulin sensitivity signaling, and inhibit apoptosis of pancreatic β-cells, which are insulin-producing cells, thereby exhibiting a blood glucose-lowering effect. Furthermore, this invention also relates to peptides with anti-diabetic and anti-obesity activities and their uses. The peptides of this invention have activities that inhibit insulin resistance signaling, promote insulin sensitivity signaling, and promote lipolysis in adipocytes.

The present invention provides an oral composition that can be used for anti-obesity, suppressing fat absorption, suppressing an increase in neutral fat, suppressing sugar absorption, suppressing an increase in blood sugar level, reducing body fat, or reducing BMI. [Solution] An oral composition containing gallic acid and ellagic acid, wherein the mass ratio of gallic acid to ellagic acid in the composition is gallic acid:ellagic acid = 1:0.01 to 0.7. The oral composition is preferably used for one or more purposes selected from anti-obesity, suppression of fat absorption, suppression of increase in triglyceride levels, suppression of sugar absorption, suppression of increase in blood glucose levels, reduction of body fat, and reduction of BMI. The oral composition preferably further contains chebulic acid.

The present invention relates to a pharmaceutical composition for preventing or treating obesity, and a food composition for preventing or improving obesity, comprising an extracellular vesicle derived from a Bifidobacterium spp. strain as an active ingredient. The composition of the present invention has the effect of reducing body weight in an obese animal model, reducing the amount of neutral fat in the liver and total cholesterol in the blood and the weight of white fat that are increased in an obese animal model, and reducing fat accumulation in the liver and brown adipose tissue and the size of white adipose cells without causing a decrease in appetite. In addition, the extracellular vesicle of the present invention has the effect of inhibiting fat synthesis in adipocytes that have induced fat accumulation. As such, the extracellular vesicle derived from a Bifidobacterium spp. strain of the present invention exhibits an excellent anti-obesity effect, and may be effectively utilized as a pharmaceutical composition for preventing or treating obesity.

The invention relates to the technical field of weight-losing health-care food, in particular to an anti-obesity prebiotic-postbiotic compound preparation for targeting intestinal flora. The anti-obesity prebiotic-postbiotic compound preparation is prepared from the following raw materials in parts by weight: 800 to 1200 parts of whey protein powder, 400 to 800 parts of bifidobacterium lactis, 500 to 800 parts of potato extract, 300 to 600 parts of chestnut powder, 200 to 400 parts of yeast powder and 1000 to 1500 parts of dietary fiber auxiliary materials, by improving the internal environment of the human body instead of simply limiting calorie intake, the health weight management system can help a user to establish a long-term stable health weight management mechanism, and the comprehensive effects of health weight reduction and difficulty in rebounding are achieved.

The present application relates to a kaurane diterpenoid compound D-33 extracted and separated from the roots of Euphorbia griffithii Hook., a preparation method and uses thereof. Bioactivity tests show that the compound D-33 has a significant weight loss effect in a high-fat diet-induced obese mouse model, can effectively activate uncoupling protein 1 (UCP1) in vitro, and can be used for preparing a thermogenic anti-obesity drug.

The invention discloses a polypeptide compound. The polypeptide compound is formed by covalently connecting small-molecule polypeptide with an amino acid sequence of Cys-Ser-Phe with gold nanoparticles through sulfydryl of cysteine residues, the polypeptide compound disclosed by the invention can be used for remarkably improving the stability and bioavailability of peptide medicines, effectively inhibiting appetite, reducing food intake, reducing body weight and improving glycometabolism and insulin sensitivity. In a diet-induced obesity (DIO) mouse model, the polypeptide compound shows an excellent anti-obesity effect, fat accumulation can be remarkably reduced, abnormal glucose tolerance of a mouse induced by high fat diet can be improved, the tolerance of an organism to glucose and insulin sensitivity are enhanced, and the polypeptide compound is simple and convenient in preparation process, suitable for industrial production and suitable for industrial production. The method can be widely applied to development and preparation of anti-obesity special medical foods, health care products and medicines.

The invention discloses a bacterial strain with an effect of preventing and treating obesity and application of the bacterial strain, the bacterial strain is Lactobacillus paracasei Biohalo 27, the bacterial strain is preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.34917, the preservation number is CGMCC NO.34917, the preservation number is CGMCC NO.34917, the preservation number is CGMCC NO.34917, the preservation number is CGMCC NO.34917, and the preservation number is CGMCC NO.34917. The preservation time is June 16, 2025; according to the invention, a strain with the effect of preventing and treating obesity is obtained by screening, and the lactobacillus paracasei Biohalo 27 plays an anti-obesity role by regulating lipid metabolism, improving insulin sensitivity, inhibiting inflammatory response and relieving liver fatty degeneration; and important experimental basis and theoretical support are provided for application of the novel probiotic preparation in prevention and treatment of obesity and related metabolic diseases.

The present disclosure is directed to engineered probiotic bacteria capable of producing anti-obesity therapeutic molecules. More specifically, bacteria are engineered to express N-lactoyl-phenyalanine (Lac-Phe), an exercise inducible molecule capable of reducing food intake and suppressing obesity, driven by a high-fat diet. Also disclosed are methods of using the engineered bacteria to treat and protect individuals from obesity.

This invention provides peptides with anti-obesity and / or anti-diabetic activity, composed of the amino acid sequence of Sequence 1 or Sequence 2. These peptides inhibit fat accumulation, reduce the size of adipocytes, and increase the expression of phosphorylated hormone-sensitive lipase, adenosine monophosphate-activated protein kinase-α1, and comparative gene recognition-58 (CGM-58), which are lipolysis factors, thereby breaking down accumulated fat. This not only exhibits excellent anti-obesity effects but also effectively reduces blood glucose levels, increasing the expression of adiponectin and adenosine monophosphate-activated protein kinase (CGM-58), which improve insulin resistance; increasing the expression of glucose transporter protein 4 (a glucose transport channel); and increasing the expression of insulin receptor substrate-1 (an insulin receptor signaling protein), thus exhibiting excellent effects against diabetes. The peptides of this invention can be effectively used in the prevention or treatment of obesity and / or diabetes.

The invention belongs to the technical field of preparation of plant fiber powder, and particularly relates to plant fiber powder and application thereof in preparation of weight-reducing products. The white kidney bean fiber powder, the apple fiber powder, the chicory fiber powder and the mushroom fibers are subjected to enzymolysis, the oat fiber powder, the soybean fiber powder and the corn fiber powder are subjected to fermentation modification, full release of active substances of all the raw materials is promoted, and the prepared plant fiber powder is rich in dietary fibers, vitamins and mineral substances and has the effects of improving the immunity of human bodies and improving the immunity of human bodies. The health can be maintained, and meanwhile, the intestinal health and immunoregulation can be promoted; the nutrition is guaranteed, and meanwhile, the anti-obesity and anti-oxidation effects can be achieved; in addition, the absorption and bioavailability of the plant fiber powder are improved by using the resistant fiber powder, so that the plant fiber powder is gradually released in an organism and plays a long-acting role. Therefore, the plant fiber powder prepared by the invention can be used for preparing weight-reducing products, and the preparation method is simple, convenient, green and safe.

The present invention relates to a novel therapeutic agent capable of treating muscle diseases, metabolic diseases, and bone diseases by simultaneously inhibiting the activin type II receptor and myostatin. Specifically, the invention relates to a bispecific protein comprising an anti-ActRII antibody and an anti-Myostatin antibody, and the use thereof. The simultaneous inhibition of the activin type II receptor and myostatin according to the present invention exhibits excellent effects of muscle growth and bone differentiation as well as weight loss; thus, it resolves the problem of muscle loss, which is a side effect of existing anti-obesity treatments, and can effectively improve various metabolic diseases. Therefore, the bispecific protein of the present invention can be utilized in various fields for the improvement and treatment of muscle diseases, metabolic diseases, and bone diseases.

The present invention relates to an anti-obesity composition comprising a citrus leaf extract as an active ingredient. The composition comprising the citrus leaf extract according to the present invention has a high content of hesperidin, inhibits adipocyte differentiation and adipocyte synthesis, and exhibits a body weight loss effect even in an obese animal model induced by a high-fat diet. In addition, the composition comprising the citrus leaf extract of the present invention has no cytotoxicity and thus can be safely used for the human body. Accordingly, the composition comprising the citrus leaf extract according to the present invention is expected to be very advantageously used as a pharmaceutical composition, a functional food composition, and a feed composition for preventing or alleviating obesity.

The present invention relates to a composition for preventing or treating a metabolic disease using a strain expressing a tartrate dehydratase or a combination therapy comprising the same, according to one aspect, when a fermentative Lactobacillus mucus strain expressing a tartrate dehydratase is administered in combination with tartaric acid, citric acid or a substance each comprising the same, due to the synergistic effect of anti-obesity activity, the composition is very effective for preventing or treating metabolic diseases.

The present invention relates to a peptide complex having an antidiabetic activity and to a use thereof. The peptide complex of the present invention promotes uptake of glucose into cells, suppresses insulin resistance signals, promotes insulin sensitivity signals, and suppresses the death of pancreatic beta cells, which are insulin-producing cells, thereby exhibiting an effect of lowering blood glucose levels. In addition, the present invention relates to a peptide having an antidiabetic activity and an antiobesity activity and to a use thereof. The peptide of the present invention has an activity of suppressing insulin resistance signals, promoting insulin sensitive signals, and promoting fat decomposition in adipocytes.

The invention discloses application of betaine in preparation of a product for losing weight and treating metabolic disorder. The betaine is applied to improvement and treatment of obesity and related diseases caused by high-fat diet for the first time. Experiments prove that the betaine can significantly inhibit adipogenesis of 3T3-L1 preadipocytes and reduce fat accumulation; animal experiments prove that the betaine can improve glucose and lipid metabolism disorder caused by high fat diet and can relieve liver and kidney injury, inflammation and the like caused by high fat diet, so that the betaine has a prospect of being applied to preparation of medicines for preventing, relieving and treating obesity induced by high fat and related diseases thereof. And a new direction is provided for the development of anti-obesity preparations.

The present invention relates to a structuring fat containing exclusively vegetable oils in its composition, free of palm oil and derivatives thereof, low saturated fat content, anti-obesogenic characteristics and satiety effect. The present invention also relates to a food product with a spreadable and / or soft texture comprising said structuring fat, as well as to the process for manufacturing the referred food product with spreadable and / or soft texture. Furthermore, the present invention relates to the uses of the structuring fat for the preparation of products (mainly spreads, cookie fillings, chocolate fillings, bakery fillings and cocoa- containing products).

The present invention relates to Akkermansia muciniphila SNUG-61027 strain (accession number KCTC 13530BP) and use thereof, specifically, a composition for suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases, comprising the strain, or a culture solution thereof, etc. or a B2UM07 protein isolated therefrom as an active ingredient, and use thereof for suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases, and a method of suppressing appetite or preventing, ameliorating, alleviating or treating metabolic diseases using the same are provided. Through this, among the anti-obesity effects, not only weight reduction and glucose homeostasis regulation, but also the effect on brown fat and the effect of secreting appetite regulating hormones are exhibited.

The invention discloses a compound with a structural formula shown in the specification, a diet-induced obesity (DIO) mouse model is constructed, the compound mL-P is used for treating a DIO mouse through intraperitoneal injection, and the experimental result shows that the compound mL-P can effectively inhibit the appetite of the mouse, reduce the food intake and reduce the body weight; the compound mL-P can obviously reduce fat accumulation, improve abnormal glucose tolerance of mice induced by high fat diet and enhance the tolerance of the body to glucose and insulin sensitivity, has no cytotoxicity, is simple and convenient in preparation process, is suitable for industrial production, and can be widely applied to development and preparation of anti-obesity drugs; .

The present invention provides a preparation method and application of a protein nanocage loaded with tuna peptides, specifically including the construction and modification of ferritin nanocages, and the extraction, screening, and embedding of tuna active peptides. The tuna active peptides are encapsulated in ferritin nanocages modified with ferulic acid and delivered to the intestines in a targeted manner. They interact with anorexigenic hormone receptors, regulate the production of anorexigenic hormones such as cholecystokinin, glucagon-like peptide 1, and PYY, control appetite after a normal diet, and enhance the body's sense of fullness, thereby reducing food intake and weight loss, thereby playing a role in regulating obesity. In the present invention, ferritin nanocages are modified with ferulic acid. The carboxyl and phenolic hydroxyl groups in the ferulic acid interact with the amino end of the outer surface of the ferritin nanocage, giving the ferritin nanocages the function of being resistant to gastric juice environment. They can exist stably in the stomach of the body without being decomposed, thereby being decomposed in the intestines and exerting their precise targeted effects, laying the foundation for anti-obesity research.

The invention relates to the technical field of new application of natural active ingredients, in particular to application of cembratriene glycol in preparation of a medicine for inhibiting lipid accumulation and a product of the cembratriene glycol. The cembratriene glycol (CBT) is alpha-cembratriene glycol or beta-cembratriene glycol, and the cembratriene glycol has the metabolic effects of inhibiting adipocyte differentiation and improving insulin resistance, and can be used as a precursor of a medicine or health food for obesity-related metabolic disorders. The cembratrienediol can obviously reduce the content of triglyceride, so that preadipocyte differentiation and lipid accumulation are effectively inhibited, glucose uptake of insulin-resistant cells is obviously improved, and the cembratrienediol is a natural anti-obesity candidate and can be used for preparing a medicine for treating obesity. A new thought and a potential technical means are provided for developing medicines and functional foods for preventing or treating obesity, diabetes, fatty liver and other metabolism-related diseases.

The invention belongs to the technical field of medicines, and particularly relates to application of kinetin in preparation of medicines for preventing and / or treating obesity, fatty liver and liver injury induced by high fat. The kinetin has a potential anti-obesity effect. Results of embodiments show that the kinetin can significantly reduce weight gain of mice caused by high fat induction, and after the kinetin is administered, the body type and white fat of the mice are reduced, the glucose tolerance is increased, the insulin sensitivity is increased, and the UCP1 (uncoupling protein 1) level of brown fat of a kinetin administration group is increased, which indicates that the kinetin can play a role in resisting obesity.